126 related articles for article (PubMed ID: 38198953)
21. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
Yang X; Gao Y; Liu Q; Wan L; Liu H; Bian W; Du Y; Huang C
Oncol Rep; 2021 Feb; 45(2):459-468. PubMed ID: 33416163
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
24. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
25. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
26. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
27. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
28. Plumbagin inhibited AKT signaling pathway in HER-2 overexpressed-endocrine resistant breast cancer cells.
Sakunrangsit N; Ketchart W
Eur J Pharmacol; 2020 Feb; 868():172878. PubMed ID: 31863768
[TBL] [Abstract][Full Text] [Related]
29. Identification of estrogen receptor down-regulators for endocrine resistant breast cancer.
Li Y; Orahoske CM; Urmetz SM; Zhang W; Huang Y; Gan C; Su B
J Steroid Biochem Mol Biol; 2022 Nov; 224():106162. PubMed ID: 35932957
[TBL] [Abstract][Full Text] [Related]
30. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
31. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
[TBL] [Abstract][Full Text] [Related]
32. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
[TBL] [Abstract][Full Text] [Related]
33. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
[TBL] [Abstract][Full Text] [Related]
34. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
Ayoub NM; Alkhalifa AE; Ibrahim DR; Alhusban A
Med Oncol; 2021 Jan; 38(1):8. PubMed ID: 33449292
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
Liu H; Wang SH; Chen SC; Chen CY; Lin TM
BMC Cancer; 2019 Feb; 19(1):176. PubMed ID: 30808421
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
[TBL] [Abstract][Full Text] [Related]
37. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
38. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
39. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
Dowsett M; Nicholson RI; Pietras RJ
Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
[TBL] [Abstract][Full Text] [Related]
40. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
